KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial.Lancet Diabetes EndocrinolPMID 40318682无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis.LupusPMID 40322925PMC121417692025-Jun0.98未发现恶性肿瘤人群证据。待处理
Esophagus-sparing radiotherapy for complicated spinal metastases (ESO-SPARE). A randomized phase III clinical trial.Radiother OncolPMID 40324910无 PMCID2025-Jun0.95The trial is a randomized phase III study in human oncology (spinal metastases). However, the intervention is radiotherapy (esophagus-sparing vs. standard), not a drug-containing regimen. Furthermore, the co-primary endpoints are patient-reported dysphagia and ambulatory function, which are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS, RFS, TTP) or analyses based on Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the eligibility criteria for this cohort.待处理
Bacterial Infections in Patients With Severe Alcohol-Associated Hepatitis: Drivers of Organ Failure and Mortality.Liver IntPMID 40332100PMC120576532025-Jun0.98未发现恶性肿瘤人群证据。部分完成
EFFICACY AND SAFETY OF LIDOCAINE WITH CLONIDINE FOR MAXILLARY INFILTRATION ANESTHESIA IN PATIENTS WITH DIABETES MELLITUS TYPE 2: DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL.J Evid Based Dent PractPMID 40335197无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
ANTIPLAQUE AND ANTIGINGIVITIS EFFECTS OF A NOVEL ORAL CARE REGIMEN FEATURING STANNOUS FLUORIDE TOOTHPASTE, A UNIQUE TOOTHBRUSH, AND CETYLPYRIDINIUM CHLORIDE MOUTHWASH: A RANDOMIZED CLINICAL TRIAL.J Evid Based Dent PractPMID 40335199无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Midazolam with fentanyl for endobronchial ultrasound-guided transbronchial needle aspiration: a randomized, double-blind, phase III study.Lung CancerPMID 40345066无 PMCID2025-Jun0.95The record describes a phase III randomized trial but fails to meet key eligibility criteria: the study is not an oncology therapeutic trial (it focuses on procedural sedation for a diagnostic procedure), the drug intervention is not an anticancer therapy, and the primary endpoint is not a time-to-event efficacy endpoint. Therefore, it is excluded.待处理
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40349716无 PMCID2025-Jun1.00命中用户提供的消化道肿瘤阳性参考集。无 KM 图
An Adult Population Pharmacokinetic Model to Simulate Subcutaneous Administration of a Fixed Dose of Furosemide in Adolescents with Heart Failure and Volume Overload.Clin PharmacokinetPMID 40360952PMC121591252025-Jun0.98未发现恶性肿瘤人群证据。待处理
Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study.Radiother OncolPMID 40379410无 PMCID2025-Jun0.95The study is a randomized Phase III trial in oncology (breast cancer) with original results. However, it is excluded because it does not involve a drug-containing intervention (it compares radiotherapy schedules) and its primary endpoint is a patient-reported normal tissue effect (safety/toxicity), not a time-to-event efficacy endpoint.待处理
180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial.Lancet Child Adolesc HealthPMID 40379431无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial.Lancet NeurolPMID 40409314无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Health-related quality-of-life profile and clinical outcomes in first-line advanced renal cell carcinoma: a modeling analysis based on the CheckMate 9ER study.ESMO OpenPMID 40412006PMC121525432025-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Randomized Trial of Lung and Diaphragm Protective Ventilation in Children.NEJM EvidPMID 40423397无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma.ESMO OpenPMID 40435872PMC121585212025-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA.ESMO Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:非 KM 图;Figure 3:非 KM 图;Figure 4:森林图/亚组分析图;Figure 5:非 KM 图。PMID 40446626PMC121668242025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.Lancet HaematolPMID 40447351无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40449498无 PMCID2025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.ESMO Open已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图。PMID 40460679PMC121670862025-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials.Eur J NeurolPMID 40462564PMC121343912025-Jun0.98未发现恶性肿瘤人群证据。待处理
Neonatal BCG vaccination to prevent asthma: Results from the MIS BAIR randomized controlled trial.Pediatr Allergy ImmunolPMID 40464744PMC121360152025-Jun0.98未发现恶性肿瘤人群证据。待处理
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).ESMO Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:生活质量量表图;Figure 3:生活质量量表图。PMID 40472660PMC121730082025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.Ann HematolPMID 40515823PMC122834652025-Jun0.85The report describes Phase III randomized trials of a drug intervention in humans, but the primary efficacy endpoint is patient-reported outcomes (PROs) and quality of life, not a time-to-event outcome. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint.待处理
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study.Curr Med Res Opin疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40528576无 PMCID2025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease.Alzheimers DementPMID 40545559PMC121831052025-Jun0.98未发现恶性肿瘤人群证据。待处理
Clinical efficacy of Shaomazhijing granules in the treatment of Tourette's syndrome: a randomized controlled trial.HereditasPMID 40450353PMC121258442025-May-310.98未发现恶性肿瘤人群证据。待处理
Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial.Br J SurgPMID 40474841无 PMCID2025-May-310.85The study is a randomized Phase III trial with a drug intervention, but the abstract does not report any time-to-event efficacy outcomes (like OS or PFS) with Kaplan-Meier or HR data. It focuses on surgical details and response rates, which are not the required primary/key secondary endpoint.待处理
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death.N Engl J MedPMID 40167274无 PMCID2025-May-290.98未发现恶性肿瘤人群证据。待处理
A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.N Engl J MedPMID 40174237无 PMCID2025-May-290.98未发现恶性肿瘤人群证据。待处理
Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.BMC MedKM panel re-extraction failedPMID 40437469PMC121211352025-May-280.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study.Blood AdvPMID 40085955PMC121438162025-May-270.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy.J Am Coll CardiolPMID 40099774无 PMCID2025-May-270.98未发现恶性肿瘤人群证据。待处理
Prothrombin Complex Concentrate vs Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: The FARES-II Multicenter Randomized Clinical Trial.JAMAPMID 40156829PMC119550852025-May-270.98未发现恶性肿瘤人群证据。待处理
Metformin for Knee Osteoarthritis in Patients With Overweight or Obesity: A Randomized Clinical Trial.JAMAPMID 40274279PMC120228622025-May-270.98未发现恶性肿瘤人群证据。待处理
Modeling Disease Progression and Placebo Response in Huntington Disease: Insights From Enroll-HD and GENERATION HD1 Cohorts.NeurologyPMID 40315394PMC120570222025-May-270.98未发现恶性肿瘤人群证据。待处理
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy.J Am Coll CardiolPMID 40398971无 PMCID2025-May-270.98未发现恶性肿瘤人群证据。待处理
Interventional arterial chemotherapy versus sorafenib for advanced hepatocellular carcinoma in China: a health economic evaluation of open-label, randomised, phase 3 study.BMJ OpenPMID 40436447PMC121216052025-May-270.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40349714无 PMCID2025-May-241.00命中用户提供的消化道肿瘤阳性参考集。无 KM 图
Major depressive disorder in children and adolescents is associated with reduced hair cortisol and anandamide (AEA): cross-sectional and longitudinal evidence from a large randomized clinical trial.Transl PsychiatryPMID 40413177PMC121035552025-May-240.98未发现恶性肿瘤人群证据。待处理
HSK21542 in patients with postoperative pain: two phase 3, multicentre, double-blind, randomized, controlled trials.Nat CommunPMID 40413233PMC121035822025-May-240.98未发现恶性肿瘤人群证据。待处理
Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis.Clin Exp DermatolPMID 39680511无 PMCID2025-May-230.98未发现恶性肿瘤人群证据。待处理
Psychometric validation of the EORTC QLQ-OES18 in patients with advanced or metastatic esophageal squamous cell carcinoma.J Patient Rep OutcomesPMID 40397297PMC120957462025-May-210.90This is a quality-of-life/psychometric validation study derived from a Phase III randomized trial. It does not report the primary or key secondary time-to-event efficacy results (e.g., OS, PFS) of the parent oncology trial. Therefore, it is excluded based on report_type and endpoint.待处理
Associations of pretreatment emotional distress with adherence to therapy for patients with locally advanced rectal cancer: a post hoc analysis of the Chinese FOWARC phase 3 randomized clinical trial.BMC MedPMID 40399932PMC120967672025-May-210.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40048691无 PMCID2025-May-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial.JAMAPMID 40121537PMC119314252025-May-200.95The study is a randomized, phase III oncology trial in humans with original primary results. However, it is excluded because it lacks a drug-containing intervention (comparing diagnostic biopsy techniques) and does not report a time-to-event efficacy endpoint as defined.待处理
High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011.J Clin OncolPMID 40193822PMC120840152025-May-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.CirculationPMID 40255182PMC120888842025-May-200.98未发现恶性肿瘤人群证据。待处理
Comparing Major Gastrointestinal Bleeding in Patients Receiving Edoxaban Versus Warfarin After Transcatheter Aortic Valve Replacement: Results From the Randomized ENVISAGE-TAVI AF Trial.J Am Heart AssocPMID 40371611PMC121846172025-May-200.98未发现恶性肿瘤人群证据。待处理
Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12.J Clin Endocrinol MetabPMID 39243386PMC120864102025-May-190.98未发现恶性肿瘤人群证据。待处理
Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1.J Clin Endocrinol MetabPMID 39378125PMC120863902025-May-190.98未发现恶性肿瘤人群证据。待处理